Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives

Immune-checkpoint inhibitors: long-term implications of toxicity

(2022) Douglas B. Johnson et al.   Nature Reviews Clinical Oncology

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy

(2021) Bin Wang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression

(2021) Xiaolei Li et al.   ONCOGENE

Therapeutic Targeting of Checkpoint Receptors within the DNAM-1 Axis

(2021) Zoya Alteber et al.   Cancer Discovery

Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma

(2021) Zhuomao Mo et al.   Frontiers in Immunology

CD96 Correlates With Immune Infiltration and Impacts Patient Prognosis: A Pan-Cancer Analysis

(2021) Wenrui Ye et al.   Frontiers in Oncology

COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade

(2021) Kyle Hansen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Advances in immunotherapy for hepatocellular carcinoma

(2021) Bruno Sangro et al.   Nature Reviews Gastroenterology & Hepatology

TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma

(2021) Itay Raphael et al.   Frontiers in Immunology

TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma

(2021) Zhouhong Ge et al.   Cellular and Molecular Gastroenterology and Hepatology

Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis

(2021) Chuanrong Chen et al.   BIOMATERIALS

The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer

(2021) William A. Freed-Pastor et al.   CANCER CELL

Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy

(2021) Baokang Wu et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients

(2021) Katsuhiro Yoshikawa et al.   PLoS One

MET amplification attenuates lung tumor response to immunotherapy by inhibiting STING

(2021) Yong Zhang et al.   Cancer Discovery

PD-1 and TIGIT Are Highly Co-Expressed on CD8+ T Cells in AML Patient Bone Marrow

(2021) Ling Xu et al.   Frontiers in Oncology

DDX60 Is Associated With Glioma Malignancy and Serves as a Potential Immunotherapy Biomarker

(2021) Jingwen Zhang et al.   Frontiers in Oncology

Sequential Single Cell Transcriptional and Protein Marker Profiling Reveals Tigit As a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin's Lymphoma

(2021) Zachary Jackson et al.   BLOOD

Simultaneous blockade of TIGIT and HIF-1α induces synergistic anti-tumor effect and decreases the growth and development of cancer cells

(2021) Mehrdad Fathi et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells

(2021) Young-Ho Lee et al.   MOLECULAR THERAPY

TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells

(2021) Liang Mao et al.   ORAL ONCOLOGY

Radical or Not-So-Radical Prostatectomy: Do Surgical Margins Matter?

(2021) Ioanna Maria Grypari et al.   Cancers

Organized Chaos: Deciphering Immune Cell Heterogeneity’s Role in Inflammation in the Heart

(2021) Alexa Corker et al.   Biomolecules

CD96 functions as a co‐stimulatory receptor to enhance CD8 + T cell activation and effector responses

(2020) Eugene Y. Chiang et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Combined evaluation of the expression status of CD155 and TIGIT plays an important role in the prognosis of LUAD (lung adenocarcinoma)

(2020) Yu Sun et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Calreticulin Blockade Attenuates Murine Acute Lung Injury by Inducing Polarization of M2 Subtype Macrophages

(2020) Zhilong Jiang et al.   Frontiers in Immunology

The future of cancer immunotherapy: microenvironment-targeting combinations

(2020) Yonina R. Murciano-Goroff et al.   CELL RESEARCH

Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma

(2020) Ailin Lepletier et al.   CLINICAL CANCER RESEARCH

Hepatocellular Carcinoma Cells Upregulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice

(2020) David Kung-Chun Chiu et al.   GASTROENTEROLOGY

The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers

(2020) Julian Smazynski et al.   GYNECOLOGIC ONCOLOGY

Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).

(2020) Delvys Rodriguez-Abreu et al.   JOURNAL OF CLINICAL ONCOLOGY

CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy

(2020) Hyung-seung Jin et al.   Cancer Immunology Research

LAG3(LAG-3,CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma

(2020) Niklas Klümper et al.   Journal for ImmunoTherapy of Cancer

Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure

(2020) Sarah Waliany et al.   Annual Review of Pharmacology and Toxicology

A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade

(2020) Linlin Ma et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

TIGIT expression is associated with T-cell suppression and exhaustion and predicts clinical outcome and anti-PD-1 response in follicular lymphoma

(2020) Zhi-Zhang Yang et al.   CLINICAL CANCER RESEARCH

Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma

(2020) Ester Lozano et al.   CLINICAL CANCER RESEARCH

IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma

(2020) Joe-Marc Chauvin et al.   CLINICAL CANCER RESEARCH

CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma

(2020) Kyle B. Lupo et al.   Journal of Hematology & Oncology

CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma

(2020) Fangkun Liu et al.   Scientific Reports

Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity

(2020) Adi Reches et al.   Journal for ImmunoTherapy of Cancer

Characterization of the DNAM-1, TIGIT and TACTILE Axis on Circulating NK, NKT-Like and T Cell Subsets in Patients with Acute Myeloid Leukemia

(2020) Isabel Valhondo et al.   Cancers

Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic Syndromes

(2020) Fanqiao Meng et al.   Frontiers in Oncology

Immune and Clinical Features of CD96 Expression in Glioma by in silico Analysis

(2020) Qiang Zhang et al.   Frontiers in Bioengineering and Biotechnology

Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR

(2020) Xiuman Zhou et al.   Cell Communication and Signaling

Direct interaction between CD155 and CD96 promotes immunosuppression in lung adenocarcinoma

(2020) Hui Zhang et al.   Cellular & Molecular Immunology

Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy

(2020) Marianne Weulersse et al.   IMMUNITY

CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells

(2020) Matthias Braun et al.   IMMUNITY

A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects

(2020) Fang Yang et al.   JOURNAL OF IMMUNOLOGY

Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model

(2020) Huilin Ma et al.   Journal for ImmunoTherapy of Cancer

TIGIT in cancer immunotherapy

(2020) Joe-Marc Chauvin et al.   Journal for ImmunoTherapy of Cancer

Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models

(2020) Vincenzo Quagliariello et al.   Journal of Personalized Medicine

An increase of CD8+ T cell infiltration following recurrence is a good prognosticator in HNSCC

(2020) Yoon Kyoung So et al.   Scientific Reports

Head and neck squamous cell carcinoma

(2020) Daniel E. Johnson et al.   Nature Reviews Disease Primers

TOX-expressing terminally exhausted tumor-infiltrating CD8+ T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer

(2020) Hye Sook Han et al.   CANCER LETTERS

Identification of targets for prostate cancer immunotherapy

(2019) Antonios Papanicolau-Sengos et al.   PROSTATE

PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function

(2019) Sarah Whelan et al.   Cancer Immunology Research

CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function

(2019) Deepak Mittal et al.   Cancer Immunology Research

Interaction between nectin-1 and the human natural killer cell receptor CD96

(2019) Veronica M. Holmes et al.   PLoS One

Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab

(2019) V. Quagliariello et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Cluster of Differentiation 96 in Children with Acute Leukemia: A Single Center Cohort Study

(2019) Hanan Mohammad et al.   INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination

(2019) Mathieu Grapin et al.   Journal for ImmunoTherapy of Cancer

Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma

(2019) Lei Wu et al.   Cancer Immunology Research

Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses

(2019) Xi Chen et al.   Acta Pharmaceutica Sinica B

Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

(2019) Rachel Grosser et al.   CANCER CELL

Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer

(2019) Hauke Stamm et al.   OncoImmunology

TIGIT immune checkpoint blockade restores CD8+T cell immunity against multiple myeloma

(2018) Camille Guillerey et al.   BLOOD

CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms

(2018) Xian-Yang Li et al.   JOURNAL OF CLINICAL INVESTIGATION

CD96 expression determines the inflammatory potential of IL-9–producing Th9 cells

(2018) Katarina Stanko et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM

(2018) Alice L. Hung et al.   OncoImmunology

Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis

(2018) Heidi Harjunpää et al.   OncoImmunology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The immune checkpoint CD96 defines a distinct lymphocyte phenotype & is highly expressed on tumor-infiltrating T cells

(2018) Ailin Lepletier et al.   IMMUNOLOGY AND CELL BIOLOGY

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model

(2018) Diana Llopiz et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Human CD96 correlates to NK cell exhaustion and predicts the prognosis of human hepatocellular carcinoma

(2018) Haoyu Sun et al.   HEPATOLOGY

Structural Basis for CD96 Immune Receptor Recognition of Nectin-like Protein-5, CD155

(2018) Felix A. Deuss et al.   STRUCTURE

CBX8 and CD96 Are Important Prognostic Biomarkers of Colorectal Cancer

(2018) Xin Song et al.   MEDICAL SCIENCE MONITOR

TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy

(2017) William C. Dougall et al.   IMMUNOLOGICAL REVIEWS

Multiple myeloma

(2017) Shaji K. Kumar et al.   Nature Reviews Disease Primers

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

(2016) Leonid Cherkassky et al.   JOURNAL OF CLINICAL INVESTIGATION

Identification of CD112R as a novel checkpoint for human T cells

(2016) Yuwen Zhu et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase

(2016) Takashi Inozume et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade

(2016) Tessa Gargett et al.   MOLECULAR THERAPY

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

(2016) Danny N. Khalil et al.   Nature Reviews Clinical Oncology

Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy

(2016) S. J. Blake et al.   Cancer Discovery

Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer

(2016) Yun-Peng Peng et al.   Oncotarget

Increased Soluble CD155 in the Serum of Cancer Patients

(2016) Akiko Iguchi-Manaka et al.   PLoS One

Expressions of CD96 and CD123 in Bone Marrow Cells of Patients with Myelodysplastic Syndromes

(2015) Wei Zhang et al.   Clinical Laboratory

TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients

(2015) Joe-Marc Chauvin et al.   JOURNAL OF CLINICAL INVESTIGATION

TIGIT predominantly regulates the immune response via regulatory T cells

(2015) Sema Kurtulus et al.   JOURNAL OF CLINICAL INVESTIGATION

Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer

(2015) Satoshi Nishiwada et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

DNAM-1 controls NK cell activation via an ITT-like motif

(2015) Zhanguang Zhang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Coordinated Expression of DNAM-1 and LFA-1 in Educated NK Cells

(2015) Monika Enqvist et al.   JOURNAL OF IMMUNOLOGY

Combination cancer immunotherapy and new immunomodulatory targets

(2015) Kathleen M. Mahoney et al.   NATURE REVIEWS DRUG DISCOVERY

Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells

(2015) A. R. Sanchez-Paulete et al.   Cancer Discovery

HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade

(2015) D. M. Woods et al.   Cancer Immunology Research

Expression of CD90, CD96, CD117, and CD123 on Different Hematopoietic Cell Populations from Pediatric Patients with Acute Myeloid Leukemia

(2014) Antonieta Chávez-González et al.   ARCHIVES OF MEDICAL RESEARCH

The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function

(2014) Robert J. Johnston et al.   CANCER CELL

UPR decreases CD226 ligand CD155 expression and sensitivity to NK cell-mediated cytotoxicity in hepatoma cells

(2014) Jiuyu Gong et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Treg Cells Expressing the Coinhibitory Molecule TIGIT Selectively Inhibit Proinflammatory Th1 and Th17 Cell Responses

(2014) Nicole Joller et al.   IMMUNITY

Novel immunotherapies for hematologic malignancies

(2014) Michelle H. Nelson et al.   IMMUNOLOGICAL REVIEWS

T-cell Immunoglobulin and ITIM Domain (TIGIT) Receptor/Poliovirus Receptor (PVR) Ligand Engagement Suppresses Interferon-γ Production of Natural Killer Cells via β-Arrestin 2-mediated Negative Signaling

(2014) Man Li et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

TACTILE becomes tangible: CD96 discloses its inhibitory peculiarities

(2014) Günter Bernhardt   NATURE IMMUNOLOGY

The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions

(2014) Christopher J Chan et al.   NATURE IMMUNOLOGY

Diverse Mechanisms Regulate the Surface Expression of Immunotherapeutic Target CTLA-4

(2014) Helga Schneider et al.   Frontiers in Immunology

Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells

(2013) L. B. John et al.   CLINICAL CANCER RESEARCH

Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR

(2013) Noa Stanietsky et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

T-cell Ig and ITIM domain regulates natural killer cell activation in murine acute viral hepatitis

(2013) Jiacheng Bi et al.   HEPATOLOGY

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

(2013) H Yang et al.   LEUKEMIA

Nectin-3 (CD113) Interacts with Nectin-2 (CD112) to Promote Lymphocyte Transendothelial Migration

(2013) Elisabeth Devilard et al.   PLoS One

Combination immunotherapy approaches

(2012) C. G. Drake   ANNALS OF ONCOLOGY

Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells

(2012) S Liu et al.   CELL DEATH AND DIFFERENTIATION

Differential Expression of CD96 Surface Molecule Represents CD8+ T Cells with Dissimilar Effector Function during HIV-1 Infection

(2012) Emily M. Eriksson et al.   PLoS One

Complementary Phosphorylation Sites in the Adaptor Protein SLP-76 Promote Synergistic Activation of Natural Killer Cells

(2012) H. S. Kim et al.   Science Signaling

Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients

(2011) Beatriz Sanchez-Correa et al.   IMMUNOLOGY AND CELL BIOLOGY

DDX60, a DEXD/H Box Helicase, Is a Novel Antiviral Factor Promoting RIG-I-Like Receptor-Mediated Signaling

(2011) M. Miyashita et al.   MOLECULAR AND CELLULAR BIOLOGY

Synergistic Signals for Natural Cytotoxicity Are Required to Overcome Inhibition by c-Cbl Ubiquitin Ligase

(2010) Hun Sik Kim et al.   IMMUNITY

Identification of Endothelial Cell Junctional Proteins and Lymphocyte Receptors Involved in Transendothelial Migration of Human Effector Memory CD4+ T Cells

(2010) T. D. Manes et al.   JOURNAL OF IMMUNOLOGY

Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines

(2009) Javier G. Casado et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vγ9Vδ2 T cells

(2009) Olivier Toutirais et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity

(2009) N. Stanietsky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype

(2008) A. Soriani et al.   BLOOD

CD96 Interaction with CD155 via Its First Ig-like Domain Is Modulated by Alternative Splicing or Mutations in Distal Ig-like Domains

(2008) Dorothee Meyer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

(2008) Xin Yu et al.   NATURE IMMUNOLOGY